Lifesci Capital Weighs in on TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.78) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.48) EPS and Q3 2025 earnings at ($0.31) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million.

TARS has been the topic of several other reports. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday. Guggenheim restated a “buy” rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Trading Up 2.1 %

Shares of TARS opened at $44.48 on Friday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average is $50.97 and its two-hundred day moving average is $43.25. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The firm has a market capitalization of $1.71 billion, a P/E ratio of -11.67 and a beta of 1.01.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of TARS. Toronto Dominion Bank acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $105,714,000. Jennison Associates LLC lifted its stake in shares of Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after buying an additional 698,712 shares during the period. Lord Abbett & CO. LLC lifted its stake in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after buying an additional 685,111 shares during the period. Millennium Management LLC lifted its stake in shares of Tarsus Pharmaceuticals by 189.4% during the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock valued at $35,659,000 after buying an additional 421,495 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.